QIAGEN Enters into Collaboration with McGill University to Advance Microbiome Research
Wednesday, November 13, 2024
QIAGEN has announced a three-year collaboration with McGill University’s Centre for Microbiome Research to support advances in microbiome research.
This collaboration is set to aid deeper insights into microbial ecosystems and their potential impact on health, which can influence future diagnostic and therapeutic developments.
QIAGEN will support the McGill Centre with necessary reagents and engage in joint research initiatives to demonstrate the relevance of its products in microbiome science. Additionally, the collaboration is expected to contribute to the training of upcoming scientists, thus expanding microbiome research to new scientific fields.
As part of the agreement, QIAGEN’s products will be incorporated into experimental platforms at the McGill Centre, which will also serve as a beta-testing site to develop and refine new products for microbiome research applications.
This partnership aligns with QIAGEN’s broader strategy to advance microbiome research, complementing an earlier 2024 partnership with Penn State University in the United States to address research challenges in the field.
The McGill Centre for Microbiome Research provides infrastructure and resources aimed at advancing evidence-based knowledge for medicine and public health. Its two primary platforms are based at McGill’s Research Institute and its downtown campus.
The Gnotobiotic Animal Research Platform focuses on understanding how specific microbial communities affect health, while the Microbial Services Platform offers design and processing services for microbiome research, including sample sequencing and anaerobic culturing to identify key microbial contributors to health and disease.
Through this collaboration, QIAGEN aims to contribute to the growing field of microbiome research. QIAGEN’s product portfolio for microbiome research spans the entire scientific workflow, including sample preparation kits designed for challenging samples from human and environmental microbiomes.
To support standardisation and reproducibility, the company also offers automated sample preparation and downstream technologies such as NGS, dPCR, and qPCR, with integrated bioinformatics tools for digital analysis.
Source: qiagen.com
